Growth and safety evaluation of infant formulae containing oligosaccharides derived from bovine milk: a randomized, double-blind, noninferiority trial

BMC Pediatrics

Philippe Steenhout¹  Norbert Sprenger²  Sophie Pecquet¹  Giovanni Licata Ricottone³  Cinzia Cajozzo³  Giuseppe Puccio³  Ferdinando Meli³ 

[1] Nestlé Nutrition, Nestec Ltd, 22 av Reller, Vevey, 1800, Switzerland;Nestlé Research Center, Nestec Ltd, Vers-chez-les-Blanc, Lausanne 26, Switzerland;Dipartimento Materno Infantile, Unità Operativa di Neonatologia, Università degli Studi di Palermo, Palermo, Italy

关键词: Healthy infants;    Infant nutrition;    Bovine milk-derived oligosaccharides;    Infant formula;   

Others  :  1090402
DOI  :  10.1186/s12887-014-0306-3

 received in 2014-05-05, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

A limited number of nondigestible oligosaccharides are available for use in infant formula. This study evaluated growth and safety in infants fed formula supplemented with a mixture of bovine milk-derived oligosaccharides (BMOS). This mixture, which was generated from whey permeate, contains galactooligosaccharides and other oligosaccharides from bovine milk, such as 3′- and 6′-sialyllactose. We hypothesized that growth in infants fed BMOS-supplemented formula would be noninferior to that in infants fed standard formula.

Methods

Healthy term infants ≤14 days old were randomly assigned to standard formula (control; n = 84); standard formula with BMOS (IF-BMOS; n = 99); or standard formula with BMOS and probiotics (Bifidobacterium longum, Lactobacillus rhamnosus) (IF-BMOS + Pro; n = 98). A breastfed reference group was also enrolled (n = 30). The primary outcome was mean weight gain/day from enrollment to age 4 months (noninferiority margin: −3.0 g/day).

Results

189 (67.3%) formula-fed infants were included in the primary analysis. Mean differences in weight gain between the control and IF-BMOS and IF-BMOS + Pro groups were <1 g/day, with 97.5% confidence intervals above −3.0 g/day, indicating noninferior weight gain in the BMOS formula groups. Compared with control, infants in the BMOS groups had more frequent (p < 0.0001) and less hard (p = 0.0003) stools. No significant differences were observed between the control and BMOS groups in caregivers’ reports of flatulence, vomiting, spitting up, crying, fussing, and colic. When based on clinical evaluation by the investigator, the incidence of colic was higher (p = 0.01) in IF-BMOS than in control; the incidence of investigator-diagnosed colic was not significantly different in control and IF-BMOS + Pro (p = 0.15). Stool bifidobacteria and lactobacilli counts were higher with IF-BMOS + Pro compared with control (p < 0.05), whereas Clostridia counts were lower (p < 0.05) in both BMOS groups compared with control.

Conclusions

Infant formula containing BMOS either with or without probiotics provides adequate nutrition for normal growth in healthy term infants. Further studies are needed to fully explore the digestive tolerance of BMOS formula.

Trial registration

ClinicalTrials.gov NCT01886898 webcite. Registered 24 June 2013.

【 授权许可】

   
2014 Meli et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 2.

【 参考文献 】

• [1]Mountzouris KC, McCartney AL, Gibson GR: Intestinal microflora of human infants and current trends for its nutritional modulation. Br J Nutr 2002, 87:405-420.
• [2]Salminen SJ, Gueimonde M, Isolauri E: Probiotics that modify disease risk. J Nutr 2005, 135:1294-1298.
• [3]Newburg DS: Oligosaccharides in human milk and bacterial colonization. J Pediatr Gastroenterol Nutr 2000, 30(Suppl 2):S8-S17.
• [4]Kalliomaki M, Isolauri E: Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003, 3:15-20.
• [5]Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995, 125:1401-1412.
• [6]Newburg DS, Ruiz-Palacios GM, Morrow AL: Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005, 25:37-58.
• [7]Gyorgy P, Jeanloz RW, von Nicolai H, Zilliken F: Undialyzable growth factors for Lactobacillus bifidus var. pennsylvanicus. Protective effect of sialic acid bound to glycoproteins and oligosaccharides against bacterial degradation. Eur J Biochem 1974, 43:29-33.
• [8]Coppa GV, Pierani P, Zampini L, Carloni I, Carlucci A, Gabrielli O: Oligosaccharides in human milk during different phases of lactation. Acta Paediatr Suppl 1999, 88:89-94.
• [9]Lawley TD, Walker AW: Intestinal colonization resistance. Immunology 2013, 138:1-11.
• [10]Ninonuevo MR, Park Y, Yin H, Zhang J, Ward RE, Clowers BH, German JB, Freeman SL, Killeen K, Grimm R, Lebrilla CB: A strategy for annotating the human milk glycome. J Agric Food Chem 2006, 54:7471-7480.
• [11]Stahl B, Thurl S, Zeng J, Karas M, Hillenkamp F, Steup M, Sawatzki G: Oligosaccharides from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 1994, 223:218-226.
• [12]Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB: In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria. Mol Nutr Food Res 2007, 51:1398-1405.
• [13]Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, Lapidus A, Rokhsar DS, Lebrilla CB, German JB, Price NP, Richardson PM, Mills DA: The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci U S A 2008, 105:18964-18969.
• [14]Barile D, Tao N, Lebrilla CB, Coisson JD, Arlorio M, German JB: Permeate from cheese whey ultrafiltration is a source of milk oligosaccharides. Int Dairy J 2009, 19:524-530.
• [15]Gopal PK, Gill HS: Oligosaccharides and glycoconjugates in bovine milk and colostrum. Br J Nutr 2000, 84(Suppl 1):S69-S74.
• [16]Martin-Sosa S, Martin MJ, Garcia-Pardo LA, Hueso P: Sialyloligosaccharides in human and bovine milk and in infant formulae: variations with the progression of lactation. J Dairy Sci 2003, 86:52-59.
• [17]Zivkovic AM, Barile D: Bovine milk as a source of functional oligosaccharides for improving human health. Adv Nutr 2011, 2:284-289.
• [18]Austin S, Bénet T, Michaud J, Cuany D, Rohfritsch P. Determination of β-galactooligosaccharides by liquid chromatography.Int J Anal Chem 2014, Article ID 768406, http://dx.doi.org/10.1155/2014/768406.
• [19]Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D: Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010, 126:e526-e533.
• [20]US Food and Drug Administration: Clinical testing of infant formulas with respect to nutritional suitability for term infants [http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/InfantFormula/ucm170649.htm]
• [21]Puccio G, Cajozzo C, Meli F, Rochat F, Grathwohl D, Steenhout P: Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition 2007, 23:1-8.
• [22]World Health Organization Multicenter Growth Reference Study Group: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development [http://www.who.int/childgrowth/standards/technical_report/en/]
• [23]Boehm G, Fanaro S, Jelinek J, Stahl B, Marini A: Prebiotic concept for infant nutrition. Acta Paediatr Suppl 2003, 91:64-67.
• [24]Knol J, Scholtens P, Kafka C, Steenbakkers J, Gro S, Helm K, Klarczyk M, Schopfer H, Bockler HM, Wells J: Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breastfed infants. J Pediatr Gastroenterol Nutr 2005, 40:36-42.